Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

127.98 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
29 30 Next >
News headline image
Cracking The Code: Understanding Analyst Reviews For Incyte ↗
 
Via Benzinga
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
News headline image
Incyte Breaks Out To 17-Month High As Jakafi Demand Surges ↗
Sales of the company's two key products, Jakafi and Opzelura, jumped. 
Via Investor's Business Daily
News headline image
Peeling Back The Layers: Exploring Incyte Through Analyst Insights ↗
 
Via Benzinga
News headline image
Uncovering Noteworthy Technical Analysis Findings for INCYTE CORP (NASDAQ:INCY). ↗
NASDAQ:INCY may be ready to breakout. 
Via Chartmill
News headline image
A Look Into Incyte Inc's Price Over Earnings ↗
 
Via Benzinga
News headline image
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review ↗
The major indexes declined, but haven't fallen apart. 
Via Investor's Business Daily
News headline image
Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock ↗
Incyte reports strong Q3 earnings, driven by Jakafi growth, prompting BofA upgrade with a new price target of $90. 
Via Benzinga
News headline image
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights ↗
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio. 
Via Benzinga
News headline image
Assessing Incyte: Insights From 11 Financial Analysts ↗
 
Via Benzinga
News headline image
This Alphabet Analyst Turns Bullish; Here Are Top 5 Downgrades For Wednesday ↗
 
Via Benzinga
News headline image
Incyte to Present at Upcoming Investor Conferences
From Incyte
Via Business Wire
News headline image
Incyte Clocks Mixed Q3 Earnings, But Analyst Sees A Strong Quarter For Jakafi And Opzelura ↗
Incyte reports Q3 revenue of $1.04B, driven by strong Jakafi and Opzelura sales, and raises 2024 guidance amid competitive market challenges. 
Via Benzinga
News headline image
Corning Posts Upbeat Q3 Earnings, Joins Opera, Inari Medical, Incyte And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
News headline image
Incyte Named One of Top 5 Companies on Science Magazine’s 2024 Top Employers List
From Incyte
Via Business Wire
News headline image
Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program
From Incyte
Via Business Wire
News headline image
Incyte to Report Third Quarter Financial Results
From Incyte
Via Business Wire
News headline image
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
News headline image
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
News headline image
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate ↗
Aquestive Therapeutics hosted a virtual investor day, announcing advancements in Anaphylm and AQST-108. The company aims for FDA meetings in late 2024, targeting a 2025 NDA submission, while HC... 
Via Benzinga
News headline image
Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress
From Incyte
Via Business Wire
News headline image
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets ↗
Truist Securities has downgraded Incyte due to concerns over Jakafi's patent expiration in 2028. Jakafi, Incyte's top-selling drug, faces potential revenue decline amid generic competition. Truist... 
Via Benzinga
Topics Intellectual Property
News headline image
Wall Street Lower Ahead Of Interest Rate Move ↗
Stocks are slightly lower this afternoon, as investors hope for the Federal Open Market Committee (FOMC) to issue its first interest rate cut in four years later today. 
Via Talk Markets
News headline image
Intel Leads S&P 500 Monday, And Keeps Running Late; Apple Chipmakers Are Biggest Losers ↗
Intel kept running late on yet another big deal. 
Via Investor's Business Daily
Topics Stocks
News headline image
Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer
From Incyte
Via Business Wire
News headline image
Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium
From Incyte
Via Business Wire
News headline image
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
29 30 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.